PL1644009T3 - Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv - Google Patents

Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv

Info

Publication number
PL1644009T3
PL1644009T3 PL04777032T PL04777032T PL1644009T3 PL 1644009 T3 PL1644009 T3 PL 1644009T3 PL 04777032 T PL04777032 T PL 04777032T PL 04777032 T PL04777032 T PL 04777032T PL 1644009 T3 PL1644009 T3 PL 1644009T3
Authority
PL
Poland
Prior art keywords
compositions
hiv infection
telomerase activity
treating hiv
increasing telomerase
Prior art date
Application number
PL04777032T
Other languages
English (en)
Polish (pl)
Inventor
Calvin B. Harley
Allison C. Chin
Tsutomu Akama
Nancy Yuk-Yu Ip
Yung-Hou Phd Associate Professor Dept Of Biolochemistry Wong
David M. Miller-Martini
Original Assignee
Telomerase Activation Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telomerase Activation Sciences, Inc. filed Critical Telomerase Activation Sciences, Inc.
Publication of PL1644009T3 publication Critical patent/PL1644009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
PL04777032T 2003-06-23 2004-06-23 Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv PL1644009T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23
EP04777032.6A EP1644009B1 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
PCT/US2004/020277 WO2005000245A2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity

Publications (1)

Publication Number Publication Date
PL1644009T3 true PL1644009T3 (pl) 2018-07-31

Family

ID=33551962

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04777032T PL1644009T3 (pl) 2003-06-23 2004-06-23 Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv
PL12180710T PL2548880T3 (pl) 2003-06-23 2004-06-23 Kompozycje powodujące wzrost aktywności telomerazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12180710T PL2548880T3 (pl) 2003-06-23 2004-06-23 Kompozycje powodujące wzrost aktywności telomerazy

Country Status (24)

Country Link
US (3) US7846904B2 (https=)
EP (2) EP2548880B1 (https=)
JP (4) JP5583882B2 (https=)
KR (3) KR101465515B1 (https=)
CN (1) CN1809364B (https=)
AP (1) AP2280A (https=)
AU (2) AU2004251753C1 (https=)
BR (1) BRPI0411856A (https=)
CA (1) CA2528483C (https=)
CY (2) CY1119951T1 (https=)
DK (2) DK1644009T3 (https=)
EA (1) EA009442B1 (https=)
ES (2) ES2716528T3 (https=)
HR (2) HRP20180330T1 (https=)
HU (2) HUE043168T2 (https=)
LT (2) LT2548880T (https=)
MX (1) MXPA05013844A (https=)
NZ (1) NZ544191A (https=)
PL (2) PL1644009T3 (https=)
PT (2) PT1644009T (https=)
SI (2) SI2548880T1 (https=)
TR (2) TR201903587T4 (https=)
WO (1) WO2005000245A2 (https=)
ZA (1) ZA200509846B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
CN1809364B (zh) 2003-06-23 2010-06-16 杰龙公司 增加端粒酶活性的组合物和方法
WO2005000248A2 (en) * 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (zh) * 2005-09-08 2007-08-29 南京医科大学 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用
CN100384830C (zh) * 2006-01-12 2008-04-30 天津药物研究院 环黄芪醇类衍生物以及用途
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
LT2898887T (lt) 2006-10-30 2018-11-12 Geron Corporation Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui
KR101560844B1 (ko) 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
CN101225424B (zh) 2007-09-13 2013-05-29 天津药物研究院 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
CA2795981C (en) 2009-05-18 2017-06-27 Geron Corporation Compositions and methods for increasing telomerase activity
WO2014186603A1 (en) * 2013-05-15 2014-11-20 Fybrands Corp. Compositions for improving the hair, skin, and nails
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
CN104435370A (zh) * 2014-12-06 2015-03-25 王香平 风湿保健酒
CN104435371A (zh) * 2014-12-06 2015-03-25 郭亮 一种用于治疗关节炎的药酒
CN104491185A (zh) * 2014-12-06 2015-04-08 郭亮 一种祛风湿药酒及其制备方法
KR20160069857A (ko) 2014-12-09 2016-06-17 (주)스피어테크 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법
CN104817610A (zh) * 2015-03-15 2015-08-05 北京化工大学 利用硫酸水解制备环黄芪醇的方法
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2016161192A1 (en) 2015-04-03 2016-10-06 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106474094A (zh) * 2015-08-31 2017-03-08 南京理工大学 一种环黄芪醇电纺纤维膜及其制备方法
WO2017044454A1 (en) 2015-09-11 2017-03-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106307522A (zh) * 2016-11-06 2017-01-11 谭淞文 一种抗衰老保健品及其制备方法和食用方法
CN106831927B (zh) * 2017-02-07 2018-02-09 江西师范大学 一种黄芪甲苷的合成方法
CN108498521B (zh) * 2017-02-24 2020-05-05 北京大学 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
KR102655940B1 (ko) 2018-08-13 2024-04-11 (주)아모레퍼시픽 신규 진세노사이드, 및 이를 포함하는 항염 조성물
CN111053782B (zh) 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
KR102635196B1 (ko) 2018-10-17 2024-02-13 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 미백 조성물
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
CN109942663B (zh) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 利用双相酸水解制备环黄芪醇的方法
MX2019006749A (es) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Compuestos activadores de senescencia celular.
KR102842907B1 (ko) 2019-09-27 2025-08-07 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물
KR102842908B1 (ko) 2019-09-27 2025-08-07 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물
CN111419854B (zh) * 2020-05-18 2021-03-30 南通大学 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用
US12305233B1 (en) 2020-07-09 2025-05-20 Arizona Board Of Regents On Behalf Of Arizona Ultra-high-throughput assay for telomerase repeat addition processivity
CN113480628B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种贵州疣螈多肽tk-cath及其编码基因和应用
CN113968894B (zh) * 2021-11-05 2024-05-28 山西大学 一种用黄芪甲苷降解制备环黄芪醇的方法
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
CN119818509B (zh) * 2025-02-10 2025-10-17 山西中医药大学 黄芪醇在制备治疗或缓解帕金森病的产品中的应用
CN120137936A (zh) * 2025-03-14 2025-06-13 北京娅熙妍国际贸易有限公司 端粒酶变体及其在抗衰老中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212791A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン、その単離法およびその用途
JPS6212792A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン類の単離法
IT1259645B (it) 1992-04-10 1996-03-25 Solis Srl Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (fr) 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (ja) * 1994-02-25 1995-09-12 Pola Chem Ind Inc 動脈硬化抑制剤及びこれを含む食品又は医薬
AT402890B (de) 1994-03-16 1997-09-25 Berbi Gmbh Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
RO117328B1 (ro) * 1994-07-07 2002-01-30 Geron Corp Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice
US6162459A (en) 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (zh) 1995-08-01 2002-02-20 裴国增 灵芝口服液及其配制方法
US5785977A (en) 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (ja) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd ジンセノサイド類含有ｈｓｐ４７合成抑制剤
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
ES2302347T3 (es) 1997-01-28 2008-07-01 D'amelio, Frank Extracto hidro-etanolico de la planta centipeda cunninghamii.
US5786343A (en) 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
WO1999012519A1 (en) 1997-09-05 1999-03-18 The Procter & Gamble Company Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
DE69808790T3 (de) 1997-09-12 2009-07-16 The Procter & Gamble Co., Cincinnati Hautreinigungs- und konditionierungsartikel für haut und haar
WO1999035243A2 (en) 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
AU5338199A (en) 1998-08-09 2000-02-28 Geron Corporation Methods and compositions for inhibiting or stimulating telomerase assembly
JP2002530436A (ja) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド 増殖能を増強しかつ複製老化を防止する方法及び試薬
JP2000204091A (ja) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd 新規ベンゾジオキソ―ル誘導体
JP2000229827A (ja) * 1999-02-05 2000-08-22 Kose Corp 皮膚外用剤
JP2000229834A (ja) * 1999-02-10 2000-08-22 Kanebo Ltd 化粧料
AUPQ127399A0 (en) * 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
JP2001258505A (ja) * 2000-03-24 2001-09-25 Fancl Corp 食品組成物
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
WO2001092289A1 (en) 2000-05-31 2001-12-06 Japan Science And Technology Corporation SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1
CN1172677C (zh) 2000-07-14 2004-10-27 复旦大学附属中山医院 黄芪甲苷在制备药物组合物中的应用
AU2001275707A1 (en) 2000-07-26 2002-02-05 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
US6696094B2 (en) 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (zh) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 一种抗皮肤过敏的药物组合物及其制法和用途
CN1369276A (zh) 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
US20020182272A1 (en) 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
CN1522248A (zh) 2001-07-03 2004-08-18 田边制药株式会社 新型丁二烯衍生物,制备它的方法及合成它的中间体
JP2003089687A (ja) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd 新規ブタジエン誘導体、その製法およびその合成中間体
US20030108629A1 (en) 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (zh) * 2001-08-31 2004-09-01 上海中医药大学 具有抗心肌纤维化作用的黄芪皂甙甲
CN1406585A (zh) * 2001-09-07 2003-04-02 中国科学院上海药物研究所 一种治疗病毒性心肌炎的药物组合物
JP2003160497A (ja) * 2001-11-22 2003-06-03 Toshin Kagaku Kk 皮膚外用剤
WO2003066814A2 (en) 2002-02-04 2003-08-14 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
CN1236803C (zh) 2002-03-20 2006-01-18 郑国芃 一种治疗风湿症的中药
CN1189176C (zh) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 黄芪甲甙组合物及其制备方法
WO2004096251A1 (en) * 2003-03-26 2004-11-11 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
CA2529852A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
CN1809364B (zh) * 2003-06-23 2010-06-16 杰龙公司 增加端粒酶活性的组合物和方法
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
WO2005044179A2 (en) 2003-06-27 2005-05-19 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Also Published As

Publication number Publication date
KR20110089887A (ko) 2011-08-09
TR201802543T4 (tr) 2018-03-21
PT1644009T (pt) 2018-02-28
JP5841337B2 (ja) 2016-01-13
US7846904B2 (en) 2010-12-07
EA200600076A1 (ru) 2006-08-25
EP1644009A2 (en) 2006-04-12
CN1809364A (zh) 2006-07-26
DK2548880T3 (en) 2019-04-08
EP2548880A2 (en) 2013-01-23
CY1119951T1 (el) 2018-12-12
ZA200509846B (en) 2007-04-25
CA2528483C (en) 2012-04-10
KR101312389B1 (ko) 2013-09-27
PT2548880T (pt) 2019-02-27
AU2004251753A1 (en) 2005-01-06
JP5583882B2 (ja) 2014-09-03
ES2716528T3 (es) 2019-06-13
US20080113925A1 (en) 2008-05-15
HUE036559T2 (hu) 2018-07-30
DK1644009T3 (en) 2018-03-05
TR201903587T4 (tr) 2019-04-22
KR20130137252A (ko) 2013-12-16
AU2004251753B2 (en) 2008-11-20
CY1121447T1 (el) 2020-05-29
US20110071095A1 (en) 2011-03-24
AP2280A (en) 2011-10-31
KR20060034237A (ko) 2006-04-21
JP2014024861A (ja) 2014-02-06
US20150093455A1 (en) 2015-04-02
LT1644009T (lt) 2018-03-12
EA009442B1 (ru) 2007-12-28
JP5913253B2 (ja) 2016-04-27
WO2005000245A3 (en) 2005-05-26
NZ544191A (en) 2008-12-24
US8759304B2 (en) 2014-06-24
JP2011098991A (ja) 2011-05-19
JP2016041770A (ja) 2016-03-31
ES2666864T3 (es) 2018-05-08
MXPA05013844A (es) 2006-07-06
CN1809364B (zh) 2010-06-16
EP1644009A4 (en) 2010-04-07
JP2007524627A (ja) 2007-08-30
EP1644009B1 (en) 2017-11-29
HRP20180330T1 (hr) 2018-04-20
EP2548880B1 (en) 2019-01-09
AU2004251753C1 (en) 2009-04-09
HRP20190322T1 (hr) 2019-04-19
KR101465515B1 (ko) 2014-11-26
HUE043168T2 (hu) 2019-08-28
LT2548880T (lt) 2019-03-25
PL2548880T3 (pl) 2019-07-31
SI2548880T1 (sl) 2019-04-30
WO2005000245A2 (en) 2005-01-06
AU2008249200A1 (en) 2008-12-18
CA2528483A1 (en) 2005-01-06
AP2005003474A0 (en) 2005-12-31
SI1644009T1 (en) 2018-04-30
BRPI0411856A (pt) 2006-08-29
EP2548880A3 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
HUE036559T2 (hu) Készítmények telomeráz aktivitás fokozására és HIV fertõzés kezelésére
TWI347184B (en) Methods of treating hiv infection
TWI315986B (en) Compositions and methods for treating or preventing pneumococcal infection
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
HUP0400609A3 (en) Wet-skin treatment compositions
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
AU2002365168A8 (en) Method and composition for treating and preventing hiv infection and aids
GB0205531D0 (en) Hair treatment compositions
IL187160A0 (en) Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003301012A8 (en) Use of beta-defensins for treating hiv infections
GB0300078D0 (en) Composition for the treatment of HIV and AIDS
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
GB0326221D0 (en) Therapeutic agents,compositions,preparations and uses
AU2003275069A8 (en) Compositions and methods for preventing infection
AU2003303948A8 (en) Compositions and methods for preventing infection
AU2002360523A8 (en) Compounds to treat hiv infection and aids
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2003258177A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection
IL187889A0 (en) Compositions and methods for preventing or treating hiv infection
IL158901A0 (en) Compositions for treating infected skin and mucous membrane
ZA200709941B (en) Compositions and methods for treating HIV infection with cupredoxin and cytochrome C